Trius Raises $30 Million in Series B Financing
Trius Initiates U.S. Phase I Trial for its Oxazolidinone
Antibacterial Drug, TR-701
Trius Presents Study Results of Best-in-Class Antibiotics
in 11 Posters at ICAAC
Trius Therapeutics Recruits former J&J Clinician as Chief Medial Officer
Trius Therapeutics Recruits Merck Executive to Lead Drug Development Efforts
Trius Therapeutics Completes $20 Million Series A Financing and Names CEO